Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753 clinical trials
Also written KITE-753.
How each study uses Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- KITE-753
- 3
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2026 | 2 |
Who runs them
Industry 2 · Other 1
Kite, A Gilead Company (2) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Autologous Anti-CD19/CD20 CAR-T Cells KITE-363 (1) · Axicabtagene ciloleucel (1)
Studies
Open first, then newest update. How each study uses Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study Of KITE-753 in R/R B-Cell ALLNot yet recruitingPhase 1M.D. Anderson Cancer CenterNCT07674823Written as KITE-753
- Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell LymphomaActive, not recruitingPhase 1/2Kite, A Gilead CompanyNCT04989803Written as KITE-753
- Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyActive, not recruitingPhase 3Kite, A Gilead CompanyNCT07479797Written as KITE-753